Scrip Watch

Caplin Point Laboratories Ltd.

Scrip Sanctuaries for protection from the wildlife in this jungle of Indian Equities

Caplin Point Laboratories Ltd.

Caplin Point Laboratories Ltd.
Pharmaceuticals
FV – Rs 2; 52wks H/L – 535/304.75; TTQ – 4274 Lacs; CMP – Rs 425 (As On June 14, 2019);
Market Cap – Rs 3215 Crs

 

Caplin Point Labs
Company Equity Capital Net Worth Long Term Debt Total Sales PAT BV EPS P/E P/BV Industry P/E Promoter’s Holdings Beta
Rs Cr. Rs Cr. Rs Cr. Rs Cr. Rs Cr. Rs Rs %
2019 15.1 597 0.29 668 176.56 78.9 23.3 18.3 5.4 28.0 69.0 0.99
2018 15.1 364 0.32 539.8 144.64 48.1 19.1 22.4 8.9 28.0 69.0 0.99

Consolidated Financials and Valuations (Amt in Rs Crs unless specified)

 

Consolidated Financial Trends (Rs. Cr.):

Particulars FY19 FY18 FY17 FY16
Equity Paid Up 15.1 15.1 15.1 15.1
Networth 597 364 224 128
Total Debt 0.29 0.32 0.48 0.73
Net Sales 648.69 539.84 401.64 238.72
Other Income 19.03 12.67 9.83 3.66
PAT 176.56 144.64 96.05 45.77
Book Value (Rs) 78.9 48.1 29.7 17
EPS (Rs) 23.3 19.1 12.7 6.1

 

Management:

Mr. C. C. Paarthipan: Chairman

Dr. Sridhar Ganesan: Managing Director

Muralidharan D: Chief Financial Officer

Vinod Kumar S: Company Secretary

 

Major Non – Promoter Holdings:

Non – Promoters No. of Shares held % shares held
MATTHEWS INDIA FUND 3,870,311 5.12
IEPF 1,460,631 1.93
Bodies Corporate 1,372,737 1.82

 

Overview:

  • Caplin Point was established in 1990 to manufacture a range of ointments, creams and other external applications.
  • The Company was listed in 1994 following its Initial Public Offering (IPO) which was oversubscribed 117 times, the proceeds of which were deployed in setting up a manufacturing facility at Pondicherry. Thereafter, the Company expanded its product range and increased its production capacity.
  • The Company focused on the emerging markets of Latin America, Caribbean, Francophone and Southern Africa and is today one of the leading suppliers of Pharmaceuticals in these regions, with over 2800 product licenses across the globe.
  • The Company is entering into the Regulated Markets for Injectables through its state of the art manufacturing facility, capable of handling Liquid Injectables in Vials, Ampoules, Lyophilized Vials and Ophthalmic dosages. The facility is approved by US FDA, EU-GMP, ANVISA-Brazil and INVIMA-Colombia.

Excerpts from Gaurav’s Blog

  Rest in Peace now Gerela Saab  ! Mr S T Gerela ex GM of BSE passed away peacefully this morning We had not met in years but he always remained at the top of my mind when it came to testimonials for this is what he had said to me over a decade ago,when […] [...]

Vedanta de-listing offer price Rs 87.50~Come on Mr Anil Agarwal ! Promoter Group of  Vedanta Ltd has proposed a voluntary de-listing at an indicative offer price of Rs 87.50~are the over 7.3 lakh minority shareholders from Alibag !? …apologies to the people of Alibag Some would term this as De-listing Duplicity ~ but I would […] [...]

This is a Riskless Reliance Industries Rights Investment Strategy for those over 2.3 Million Shareholders already holding RIL shares. It is not a recommendation to buy RIL cum rights  It’s a no brainer yet I’m just penning a brief note because some have told me they hold Reliance but are skipping the Rights ! Don’t […] [...]

 Wealth is negotiable, Health is not Your Personal Well Being is more important that the Stock Market Well Being ~ Always & more so in this unfathomable ongoing Covid-19 Reality Above’s a three minute reach out by me last night to all connected with me to reinforce this .It’s also posted on Facebook , […] [...]

Yes Bank ~ Has the RBI & MOF lost it !? SEBI really is a bystander here Controversial Lock In Clause 3 Sub Clause 8 (a) in the Scheme of Reconstruction  No wonder the Finance Minister Mrs Nirmala Sitharaman, while highlighting only selected points, even when asked for details of the Scheme,did not want to […] [...]